Oriol Mirallas, Clinical Fellow in the Investigational Cancer Therapeutics (ICT) Department at the University of Texas MD Anderson Cancer Center, shared a post on X:
“ESMO 2025 has come to an end!
Loved seeing friends and colleagues from around the world.
Great discussions on:
- Early-drug development
- ctDNA
- ADCs
Inspired and grateful for the science and people.
See you soon!”
Follow the latest ESMO 2025 news on OncoDaily.
